공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 리소좀 축적질환 시장

Lysosomal Storage Diseases

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997503
페이지 정보 영문 131 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 리소좀 축적질환 시장 Lysosomal Storage Diseases
발행일 : 2021년 04월 페이지 정보 : 영문 131 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 리소좀 축적질환 시장 규모는 분석기간(2020-2027년)에 5.6%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 70억 달러에서 2027년에는 103억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 효소대체요법(ERT)은 분석기간 중 6.1%의 CAGR을 나타내고, 49억 달러에 달할 전망입니다.

세계의 리소좀 축적질환(LSD: Lysosomal Storage Diseases) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Chiesi Farmaceutici SpA
  • Greenovation Biotech GmbH
  • Horizon Pharma PLC
  • Leadiant Biosciences SpA
  • Mylan NV
  • Pfizer, Inc.
  • Protalix Biotherapeutics
  • Recordati S.p.A.
  • Sanofi Genzyme
  • Shire PLC
  • Synageva BioPharma Corporation
  • Valerion Therapeutics, LLC.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 44개사
LSH 21.04.08

Abstract:

Global Lysosomal Storage Diseases Market to Reach $10.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Lysosomal Storage Diseases estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. Enzyme Replacement Therapy (ERT), one of the segments analyzed in the report, is projected to record a 6.1% CAGR and reach US$4.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Substrate Reduction Therapy (SRT) segment is readjusted to a revised 5.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 5.2% CAGR

The Lysosomal Storage Diseases market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Cystine Depleting Agents Segment to Record 4.9% CAGR

In the global Cystine Depleting Agents segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.2 Billion in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2027.

Select Competitors (Total 44 Featured) -

  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Chiesi Farmaceutici SpA
  • Greenovation Biotech GmbH
  • Horizon Pharma PLC
  • Leadiant Biosciences SpA
  • Mylan NV
  • Pfizer, Inc.
  • Protalix Biotherapeutics
  • Recordati S.p.A.
  • Sanofi Genzyme
  • Shire PLC
  • Synageva BioPharma Corporation
  • Valerion Therapeutics, LLC.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Enzyme Replacement Therapy (ERT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Substrate Reduction Therapy (SRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Substrate Reduction Therapy (SRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Substrate Reduction Therapy (SRT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cystine Depleting Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cystine Depleting Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cystine Depleting Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Lysosomal Storage Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Rest of Europe Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Rest of Europe 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 46: Asia-Pacific Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Asia-Pacific Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Asia-Pacific 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 49: Rest of World Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of World Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of World 15-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44
Back to Top
전화 문의
F A Q